Sep 10, 2020
Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing
Aug 10, 2020
Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments
Aug 07, 2020
Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street
Aug 03, 2020
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital
Jul 21, 2020
Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy
Jun 24, 2020
Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update
Jun 16, 2020
Biohaven Presents NURTEC(TM) (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting
Jun 10, 2020
Biohaven Appoints Bob Hugin to its Board of Directors
May 18, 2020
Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC(TM) ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
May 07, 2020
Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments
Apr 27, 2020
Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC(TM) ODT in the Middle East
Apr 16, 2020
Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19
Apr 09, 2020
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection
Apr 07, 2020
Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC(TM) ODT
Mar 30, 2020
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC(TM), Dosed Every Other Day, for the Preventive Treatment of Migraine
Mar 23, 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Mar 18, 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Mar 17, 2020
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment
Mar 13, 2020
Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC(TM) ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults
Feb 27, 2020
Biohaven's NURTEC(TM) ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults